BioCentury
ARTICLE | Company News

Celladon, Servier deal

March 3, 2014 8:00 AM UTC

Celladon granted Servier an exclusive option to license ex-U.S. rights to discover, develop and commercialize ATPase Ca++ transporting cardiac muscle slow twitch 2b ( ATP2A2b; SERCA2b) modulators for Type II diabetes and other metabolic diseases. Celladon did not receive a payment for granting the option, which is exercisable after the parties complete predefined in vitro and in vivo studies. If Servier exercises the option, Celladon will receive an undisclosed upfront payment and be eligible for milestones and royalties. ...